Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Abbott India Ltd. Share Price
Day's Range
Day's Range
Low
₹26,430.00
High
₹26,970.00
Price Summary
| Previous Close | ₹26,835.00 |
|---|---|
| Day's Range | ₹26,430.00 - ₹26,970.00 |
| Open | ₹26,550.00 |
| 52 Week Range | ₹25,150.00 - ₹37,000.00 |
| Volume | 18,156 |
| Market Cap | ₹0.06 |
| Previous Close | ₹26,896.50 |
|---|---|
| Day's Range | ₹26,448.90 - ₹26,949.00 |
| Open | ₹26,879.05 |
| 52 Week Range | ₹25,164.00 - ₹35,921.55 |
| Volume | 1,361 |
| Market Cap | ₹0.06 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 4,872.16 |
|---|---|
| Market Cap (₹ in Mn) | 0.06 |
| Dividend Yield(%) | 1.81 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | 0.00 |
| P/E Ratio | 8.42 |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | 13.37 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 49.12 |
| Trade Value ( ₹ in Lacs) | 366.06 |
|---|---|
| Market Cap (₹ in Mn) | 0.06 |
| Dividend Yield(%) | 1.81 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | 0.00 |
| P/E Ratio | 8.42 |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | 13.37 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 49.12 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 16142.8 | 58489.1 |
| Expenses | N/A | N/A |
| PBT | 4875.9 | 16177.5 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 3607.8 | 12012.2 |
About Abbott India Ltd.
| Founded | 1944 |
|---|---|
| Managing Director | Kartik Rajendran |
| NSE Symbol | ABBOTINDIA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,43,972.94 | 1,834.10 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,025.88 | 6,693.70 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,477.60 | 4,358.00 | 3,101.60 - 3,101.60 |
| Lupin Ltd. | 1,11,668.12 | 2,445.00 | 1,836.80 - 1,836.80 |
| Apollo Hospitals Enterprise Ltd. | 1,11,526.57 | 7,822.00 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,10,282.52 | 1,366.60 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,381.80 | 1,306.45 | 1,138.50 - 1,138.50 |
| Max Healthcare Institute Ltd. | 98,852.37 | 1,016.35 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,505.92 | 2,371.00 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,495.43 | 939.95 | 835.50 - 835.50 |
No Records Found
Latest News
Abbott India informs about change in management
Abbott India informs about certificate
In terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, Abbott India has informed that it enclosed, Certificate issued by KFin Technologies, Registrar and Transfer Agent of the Company, for the quarter ended March 31, 2026.
The above information is a part of company’s filings submitted to BSE.
Abbott India informs about press release
Venmax Drugs and Pharmaceuticals informs about board meeting
In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Venmax Drugs and Pharmaceuticals has informed that the Meeting of the Board of Directors is scheduled to be held on Thursday, May 14, 2026 at 3.30 pm to consider and approve, the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026. Further, the Trading Window for dealing in Securities of the Company which stands closed for all the Designated Persons of the Company with effect from April 1, 2026 would continue to remain closed till May 16, 2026 i.e., till 48 hours after the approval of the Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31, 2026.
The above information is a part of company’s filings submitted to BSE.
Zydus Lifesciences informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Abbott India Ltd. is ₹26,835.00 as of 2026-05-07.
The market capitalisation of Abbott India Ltd. is ₹55,876.10 as of 2026-05-06.
The 1-year return of Abbott India Ltd. is 535.00% as of 2026-05-07.
The P/E ratio of Abbott India Ltd. is 46.17 as of 2026-05-07.
The 52-week high and low of Abbott India Ltd. are ₹37,000.00 and ₹25,150.00, respectively, as of 2026-05-07.
People Also Ask
Abbott India Ltd. provides an extensive portfolio of science-based nutritional products, diagnostic tools, and branded generic pharmaceuticals. The company holds a massive market presence in gastroenterology, women's health, specialised metabolic medications, and trusted over-the-counter medical solutions.
Abbott India Ltd. collaborates by extensively training healthcare professionals on new medical therapies and diagnostic technologies. The firm partners with large hospital networks to supply advanced laboratory diagnostic equipment and ensures important medical nutrition reaches specialised patient care units.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
